Thus, in patients with insulin resistance, the administration of Exenatide, a GLP-1 receptor agonist drug, reduces liver fat and liver enzymes, favoring the treatment of MAFLD [119,120]. The gene discussed is GLP1R; the disease is Insulin resistance.